TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients With Major Depressive Disorder and Associated Painful Physical Symptoms
Brief Summary: The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than placebo when treating depression and its associated painful symptoms.


Options:
A: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease
Brief Summary: PRT-201 is a recombinant human type-I pancreatic elastase intended for local, long-lasting dilation of the AVG venous anastomosis and outflow vein. The goal of the treatment is to improve primary patency and long-term survival of AVGs and thereby provide patients with chronic kidney disease (CKD) a reliable and durable vascular access site for hemodialysis. Recent data indicate that up to three quarters of patients have loss of graft patency at one year, indicating a substantial need for new therapies. This clinical trial will explore the safety and dilatory effect of topically administered PRT-201 on the outflow vein of a newly placed upper extremity AVG.


Options:
A: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)
B: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201; Type: EXPERIMENTAL; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): 2, PRT-201

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease
Brief Summary: PRT-201 is a recombinant human type-I pancreatic elastase intended for local, long-lasting dilation of the AVG venous anastomosis and outflow vein. The goal of the treatment is to improve primary patency and long-term survival of AVGs and thereby provide patients with chronic kidney disease (CKD) a reliable and durable vascular access site for hemodialysis. Recent data indicate that up to three quarters of patients have loss of graft patency at one year, indicating a substantial need for new therapies. This clinical trial will explore the safety and dilatory effect of topically administered PRT-201 on the outflow vein of a newly placed upper extremity AVG.


Options:
A: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)
B: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): 2, PRT-201
C: Arm Label: control group; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: Far infrared therapy; Type: EXPERIMENTAL; Interventions: Device: WSTM TY101 FIR emitter (Far infrared therapy) | Intervention Type: DEVICE; Name: WSTM TY101 FIR emitter (Far infrared therapy); Assigned to Arm(s): Far infrared therapy | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): control group
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201; Type: EXPERIMENTAL; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Brief Summary: The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.


Options:
A: Arm Label: Cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab | Arm Label: Panitumumab; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab
B: Arm Label: bevacizumab alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: Bevacizumab + erlotinib; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab alone | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): Bevacizumab + erlotinib
C: Arm Label: lenalidomide plus cetuximab; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, Drug: lenalidomide | Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): lenalidomide plus cetuximab | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide, lenalidomide plus cetuximab
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Brief Summary: The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.


Options:
A: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A
B: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
C: Arm Label: Cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab | Arm Label: Panitumumab; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab
D: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.


Options:
A: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD9668 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZD9668 Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD9668 Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.


Options:
A: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (Symbicort Turbuhaler) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (Oxis Turbuhaler) | Intervention Type: DRUG; Name: Budesonide/formoterol (Symbicort Turbuhaler); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol (Oxis Turbuhaler); Assigned to Arm(s): 2
D: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography: the CLOSE-UP I Randomized Trial
Brief Summary: Is the FemoSeal® closure device safer and more comfortable than manual compression for femoral artery access closure after coronary angiography?


Options:
A: Arm Label: Standard EVAR (IntuiTrak); Type: ACTIVE_COMPARATOR; Interventions: Device: SEVAR (IntuiTrak) | Arm Label: PEVAR (ProGlide closure); Type: EXPERIMENTAL; Interventions: Device: PEVAR (ProGlide closure) | Arm Label: PEVAR (ProstarXL closure); Type: EXPERIMENTAL; Interventions: Device: PEVAR (Prostar XL closure) | Intervention Type: DEVICE; Name: PEVAR (ProGlide closure); Assigned to Arm(s): PEVAR (ProGlide closure) | Intervention Type: DEVICE; Name: SEVAR (IntuiTrak); Assigned to Arm(s): Standard EVAR (IntuiTrak) | Intervention Type: DEVICE; Name: PEVAR (Prostar XL closure); Assigned to Arm(s): PEVAR (ProstarXL closure)
B: Arm Label: FemoSeal®; Type: EXPERIMENTAL; Interventions: Device: FemoSeal® | Arm Label: ExoSeal®; Type: EXPERIMENTAL; Interventions: Device: ExoSeal® | Arm Label: Manual compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Intervention Type: DEVICE; Name: FemoSeal®; Assigned to Arm(s): FemoSeal® | Intervention Type: DEVICE; Name: ExoSeal®; Assigned to Arm(s): ExoSeal® | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manual compression
C: Arm Label: Manual Compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Compression | Arm Label: Vascular Closure Device; Type: EXPERIMENTAL; Interventions: Device: Vascular Closure Device | Intervention Type: OTHER; Name: Manual Compression; Assigned to Arm(s): Manual Compression | Intervention Type: DEVICE; Name: Vascular Closure Device; Assigned to Arm(s): Vascular Closure Device
D: Arm Label: FemoSeal®; Type: EXPERIMENTAL; Interventions: Device: FemoSeal® | Arm Label: Manual compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Intervention Type: DEVICE; Name: FemoSeal®; Assigned to Arm(s): FemoSeal® | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manual compression

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fit For Delivery: A Study of the Effect of Exercise Intervention and Nutritional Counselling on Pregnancy Outcome.
Brief Summary: "Fit for Delivery" is a randomized, controlled study to examine the effects of an intervention during pregnancy which consists of exercise groups and nutritional counselling. The investigators will assess the outcomes of gestational weight gain, postpartum weight retention, large newborns, glucose regulation, and the incidence of complications of pregnancy and delivery such as gestational diabetes and Cesarean section.


Options:
A: Arm Label: Parents As Teachers + Lifestyle Int.; Type: EXPERIMENTAL; Interventions: Behavioral: Parents As Teachers Plus (PAT+) | Arm Label: Standard Parents as Teachers (PAT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Parents As Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Standard Parents As Teachers (PAT); Assigned to Arm(s): Standard Parents as Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Parents As Teachers Plus (PAT+); Assigned to Arm(s): Parents As Teachers + Lifestyle Int.
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and dietary education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise and dietary education; Assigned to Arm(s): Intervention
C: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Nutritional counseling + exercise groups; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional counseling + exercise groups | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutritional counseling + exercise groups; Assigned to Arm(s): Nutritional counseling + exercise groups

Answer: D